IL10 and colitis: To elucidate the underlying pathogenesis of human IBD and identify potential therapeutic targets, rodent models have been developed, such as the chemically induced dextran sodium sulfate (DSS) colitis model and genetically modified Interleukin 10 knock-out (IL-10 −/−) mice [28,29].